ABVC BIOPHARMA, INC.
For the period ended Dec 31, 2024. Filed Apr 15, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Apr 15, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Part I
Except for statements of historical fact, the information presented herein constitutes forward-looking statements. These forward-looking statements generally can be identified by phrases such as “anticipates,” “believes,” “estimates,” “expects,” “forecasts,” “foresees,” “intends,” “plans,” or other words of similar import. Similarly, statements herein that describe our business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, our ability to: successfully commercialize our technology; generate revenues and achieve profitability in an intensely competitive industry; compete in products and prices with substantially larger and better capitalized competitors; secure, maintain and enforce a strong intellectual property portfolio; attract additional capital sufficient to finance our working capital requirements, as well as any investment of plant, property and equipment; develop a sales and marketing infrastructure; identify and maintain relationships with third party suppliers who can provide us a reliable source of raw materials; acquire, develop, or identify for our own use, a manufacturing capability; attract and retain talented individuals; continue operations during periods of uncertain general economic or market conditions, and; other events, factors and risks previously and from time to time disclosed in our filings with the Securities and Exchange Commission.
Although we believe the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, we do not undertake to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
The following summarizes some, but not all, of the risks provided below. Please carefully consider all of the information discussed in Item 1A “Risk Factors” in this annual report for a more thorough description of these and other risks.
Risks Related to the Company’s Business
| ● | Risks relating to unfavorable global economic conditions, including health and safety concerns on the business, financial condition, and results of operations. |
| ● | Risks relating to no history in obtaining regulatory approval for, or commercializing, any new drug candidate. |
| ● | Risks relating to dependence on successful development, acquisition or licensing of new drugs. |
| ● | Risks relating to side effects associated with current or future products that could impact growth. |
| ● | Risks relating to product liability claims and substantial liabilities |
| ● | Risks relating to conducting clinical trials at sites outside the United States. |
| ● | Risks relating to failure in demonstrating safety and efficacy of product candidates in clinical trials. |
| ● | Risks relating to failure to achieve market acceptance. |
| ● | Risks relating to failure to enter successful collaborations or establish and maintain additional strategic partnerships |
| ● | Risks relating to termination of license agreements. |
| ● | Risks relating to dependence on one supplier for API of certain drug candidates. |
| ● | Risks relating to claims relating to improper handling, storage or disposal of hazardous chemicals and biological materials. |
| ● | Risks relating to failure to maintain and monitor the sample of drug candidates. |
Risks Related to Intellectual Property
| ● | Risks relating to improper disclosure and misappropriation of confidential information or trade secrets |
| ● | Risks relating to protection of our IP or infringement of IP rights of other parties |
| ● | Risks relating to unable to protect and enforce our IP rights throughout the world. |
Regulatory Risks Relating to Biopharmaceutical Business
| ● | Risks relating to fail or delay to obtain regulatory approval |
| ● | Risks relating to competition from more established and well-resourced companies. |
Risks Relating to Doing Business Outside the United States
| ● | Risks relating to international operations. |
Risks Related to the Company’s Financial Condition
| ● | Risks relating to our existing indebtedness. |
| ● | Risks relating to our disclosure controls and procedures and internal financial reporting controls. |
| ● | Risks relating to creation of new series of preferred stock. |
| ● | Risks relating to failure in safeguarding our computer network system. |
Risks Related to the Company’s Common Stock
| ● | Risks relating to volatility of share price. |
| ● | Risks relating to certain shareholders have substantial influence over our Company and their interests may not be aligned with the interests of our other shareholders |
| ● | Risks relating to future sales and issuances of our common stock or rights to purchase common stock |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.